NASDAQ : ASPE

Aspen Neuroscience, Inc. — Company profile

Healthcare · Biotechnology · United States

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.

Details

NameAspen Neuroscience, Inc.
SectorHealthcare
IndustryBiotechnology
Employees120
Founded2018
Ipo Date2026-10-30
CeoDamien McDevitt
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price15.00
IsinUS0449331091
Cusip044933109
Cik2124080
Sic2834

Key executives

NameTitle
Damien McDevitt, Ph.D.President, Chief Executive Officer and Director
Faheem HasnainExecutive Chairman
Dalen MeeterChief Financial Officer
Lisa Johnson-Pratt, M.D.Sasineprocel Development Lead and Chief Commercial Officer
Kim RaineriChief Technology Officer
Jeffrey BoernekeGeneral Counsel and Secretary
Thomas Daniel, M.D.Director
Douglas Fisher, M.D.Director
Cindy PerettieDirector
Caryn PetersonDirector

Contact

Address10835 Road to the Cure, Suite 100, San Diego, California 92121, United States
Phone(858) 263-1222
Websitehttps://www.aspenneuroscience.com